What changed
$ROST — HOLD 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ1 FY2027 (ends Apr) | reported May 21 | Rev $6.0B | EPS $2.02 vs $1.72 🟢 | Margin 13.4%
💡 Consensus appears to fairly reflect the earnings power after the 17% beat; no variant view of mispricing, as valuation is in-line with historical norms for Ross's growth profile, and upside from here would require sustained beat-and-raise against a cautious consumer backdrop.
🏢 Business Quality: 8 — dominant off-price retailer with consistent share gains, strong returns on capital, and a net cash balance sheet./10
📊 Valuation: fair — trailing P/E 26.4x, EV/EBITDA ~17x, FCF yield 3.7%; all metrics sit in the upper quartile of Ross’s 10-year range, leaving limited margin of...
🔮 Catalyst: Q3 FY2027 earnings (likely September/October 2026)
⚖️ Hold ROST — quality name but fully valued after a large beat; wait for a 8-10% pullback before adding.